鹭燕医药: management transactions · France · AMF SZSE:002788 FR FR · AMF Mcap 8.2Bn€
Browse the full management transaction log of 鹭燕医药, a publicly traded company based in France. Shares are listed on FR FR, under the supervision of AMF. Market capitalisation: €8.2bn. The latest transaction was filed on 28 November 2024 — Sale. Among the most active insiders: 雷鸣. Every trade is openly available.
Financial data FY ended December 2025 · cache
Income statement
Revenue 21.25 Bn€
Gross profit 1.50 Bn€ 7% margin
Net income 280.9 M€ 1.3% margin
Balance sheet & cash
Market cap 8.23 Bn€
Total debt 4.89 Bn€
Free Cash Flow 454.7 M€
Last declaration on 28 November 2024
Declarations 9 total
Executives ● Sale7 SZSE
58,000 shares
SZSE:173000008306458180 · 28 Nov 2024
Executives ● Sale7 SZSE
100,000 shares
SZSE:173000006973136860 · 27 Sept 2023
Executives ● Sale7 SZSE
116,300 shares
SZSE:173000005952609180 · 14 Oct 2022
Executives ● Sale7 SZSE
95,000 shares
SZSE:173000005937798900 · 10 Oct 2022
Executives ● Sale7 SZSE
89,200 shares
SZSE:173000005934833180 · 30 Sept 2022
Executives ● Sale11 SZSE
120,000 shares
SZSE:173000009245883100 · 31 Dec 2021
Executives ● Sale11 SZSE
35,978 shares
SZSE:173000005200999360 · 30 Dec 2021
Executives ● Sale7 SZSE
12,710 shares
SZSE:173000005173634460 · 15 Dec 2021
Executives ● Sale7 SZSE
100,000 shares
SZSE:173000005173634500 · 10 Dec 2021